126 related articles for article (PubMed ID: 24841154)
21. Molecular determinants of treatment response in acute lymphoblastic leukemia.
Campana D
Hematology Am Soc Hematol Educ Program; 2008; ():366-73. PubMed ID: 19074112
[TBL] [Abstract][Full Text] [Related]
22. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
[TBL] [Abstract][Full Text] [Related]
23. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.
Reyes-Barron C; Burack WR; Rothberg PG; Ding Y
Crit Rev Oncog; 2017; 22(5-6):559-567. PubMed ID: 29604931
[TBL] [Abstract][Full Text] [Related]
24. Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features.
de Oliveira JC; Scrideli CA; Brassesco MS; Morales AG; Pezuk JA; Queiroz Rde P; Yunes JA; Brandalise SR; Tone LG
Leuk Res; 2012 Mar; 36(3):293-8. PubMed ID: 22099053
[TBL] [Abstract][Full Text] [Related]
25. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
26. Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease.
Szczepański T; Beishuizen A; Pongers-Willemse MJ; Hählen K; Van Wering ER; Wijkhuijs AJ; Tibbe GJ; De Bruijn MA; Van Dongen JJ
Leukemia; 1999 Feb; 13(2):196-205. PubMed ID: 10025893
[TBL] [Abstract][Full Text] [Related]
27. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
28. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
[TBL] [Abstract][Full Text] [Related]
29. HOX gene expression in phenotypic and genotypic subgroups and low HOXA gene expression as an adverse prognostic factor in pediatric ALL.
Starkova J; Zamostna B; Mejstrikova E; Krejci R; Drabkin HA; Trka J
Pediatr Blood Cancer; 2010 Dec; 55(6):1072-82. PubMed ID: 20672366
[TBL] [Abstract][Full Text] [Related]
30. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
31. Persistence of E2A/PBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: correlation with chemotherapy intensity and clinical outcome.
Lanza C; Gottardi E; Gaidano G; Vivenza C; Parziale A; Perfetto F; Fornaci M; Barisone E; Madon E; Basso G; Saglio G
Leuk Res; 1996 May; 20(5):441-3. PubMed ID: 8683984
[TBL] [Abstract][Full Text] [Related]
32. Post-induction residual disease in translocation t(12;21)-positive childhood ALL.
Seyfarth J; Madsen HO; Nyvold C; Ryder LP; Clausen N; Jonmundsson GK; Wesenberg F; Schmiegelow K
Med Pediatr Oncol; 2003 Feb; 40(2):82-7. PubMed ID: 12461790
[TBL] [Abstract][Full Text] [Related]
33. Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia.
Huang A; Huang C; Tang G; Cheng H; Liu M; Ding J; Gong S; Chen Q; Zhang W; Yang J; Wang J; Hu X
Leuk Lymphoma; 2018 May; 59(5):1073-1083. PubMed ID: 28857648
[TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
35. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
[TBL] [Abstract][Full Text] [Related]
36. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
[TBL] [Abstract][Full Text] [Related]
37. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
38. High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.
Hoffmann J; Krumbholz M; Gutiérrez HP; Fillies M; Szymansky A; Bleckmann K; Zur Stadt U; Köhler R; Kuiper RP; Horstmann M; von Stackelberg A; Eckert C; Metzler M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27780. PubMed ID: 31034759
[TBL] [Abstract][Full Text] [Related]
39. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.
Spanaki A; Perdikogianni C; Linardakis E; Kalmanti M
Leuk Res; 2007 May; 31(5):639-42. PubMed ID: 16860864
[TBL] [Abstract][Full Text] [Related]
40. Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.
Passet M; Kim R; Gachet S; Sigaux F; Chaumeil J; Galland A; Sexton T; Quentin S; Hernandez L; Larcher L; Bergugnat H; Ye T; Karasu N; Caye A; Heizmann B; Duluc I; Chevallier P; Rousselot P; Huguet F; Leguay T; Hunault M; Pflumio F; Freund JN; Lobry C; Lhéritier V; Dombret H; Domon-Dell C; Soulier J; Boissel N; Clappier E
Blood; 2022 Jun; 139(24):3505-3518. PubMed ID: 35316324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
